No significant differences were observed between groups in plaque lysophosphatidylcholine content or other biomarkers , although a dose-dependent decrease in plaque matrix metalloproteinase-9 mRNA expression was observed with darapladib 80 mg ( P = 0.053 vs placebo ) .